Evidence map›Paper›PMID 38855616›Full record

ReviewExploration (Beijing, China)2024

Recent design strategies for boosting chemodynamic therapy of bacterial infections.

Junjie Zhang, Haiyang Guo, Ming Liu, Kaiyuan Tang, Shengke Li, Qiang Fang, Hengda Du, Xiaogang Zhou, Xin Lin, Yanjun Yang and 2 more

Abstract readReview
In one paragraph

Review in Exploration (Beijing, China), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junjie ZhangSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Haiyang GuoSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Ming LiuSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Kaiyuan TangSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Shengke LiMacao Centre for Research and Development in Chinese Medicine Institute of Chinese Medical Sciences University of Macau Taipa Macau SAR China.
Qiang FangSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Hengda DuSchool of Fundamental Sciences Bengbu Medical College Bengbu China.
Xiaogang ZhouAnhui Key Laboratory of Infection and Immunity, School of Basic Medicine Bengbu Medical College Bengbu China.
Xin LinSchool of Optometry and Ophthalmology and Eye Hospital, State Key Laboratory of Optometry Ophthalmology and Vision Science Wenzhou Medical University Wenzhou Zhejiang China.
Yanjun YangSchool of Electrical and Computer Engineering, College of Engineering The University of Georgia Athens Georgia USA.
Bin HuangAcademy of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatrics Fujian University of Traditional Chinese Medicine Fuzhou Fujian China.
Dongliang YangKey Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), School of Physical and Mathematical Sciences Nanjing Tech University (NanjingTech) Nanjing China.ORCID https://orcid.org/0000-0002-8605-6720

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug-resistant bacteria poses a significant threat to people's lives and health as bacterial infections continue to persist. Currently, antibiotic therapy remains the primary approach for tackling bacterial infections. However, the escalating rates of drug resistance coupled with the lag in the development of novel drugs have led to diminishing effectiveness of conventional treatments. Therefore, the development of nonantibiotic-dependent therapeutic strategies has become imperative to impede the rise of bacterial resistance. The emergence of chemodynamic therapy (CDT) has opened up a new possibility due to the CDT can convert H

Indexed as

antibacterialchemodynamic therapycombined therapynanomaterials

Identifiers

PMID38855616
PMCPMC11022619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.